SHANGHAI, China, 19-20 January 2010 – With China's new healthcare reform aiming to provide an affordable health care system to its population, pharmacoeconomics is an area receiving more attention every year. In August 2009, China announced the new National Essential Medicine List, which utilizes pharmacoeconomics as an important evaluation factor in the selection of listed drugs, demonstrating its wide recognition among the Chinese government. Capped healthcare budgets and rising drug costs have led to a high level of interest in the use of economic analysis for drug evaluation in China.
Attended by international senior executives, Chinese government officials, industry experts and leading academics, the Pharmacoeconomics and Outcomes Research Congress organized by Noppen took place on 19-20 January in Shanghai, China. The focus of the 2-day event was to bring together drug developers, government officers, and solution providers to discuss China's pharmacoeconomic development. Attendees learnt about recent breakthroughs and regulations, such as drug pricing, life-cycle management and the role of pharmacoeconomics in China's new medical reform. As well as insights into healthcare costs and results of decision making.
Opening speech at the conference was delivered by Jie Shen, Senior Director of Pricing & Market Access, Biogen Idec International GmbH, Switzerland. She gave a very thorough description on the application of HTA in pricing and reimbursement decision-making. Key speakers at the congress included Jin Chunlin, Vice Division Chief, Planning and Finance Division, Shanghai Public Health Bureau who presented the results of the Shanghai Report on Regional Health Accounts. He stated that"as the social expenditure on health is rising up, the individual expenditure on health is dropping down, and the government expenditure on health is going steadily." Jennifer Sung, Executive Director, Global Health Economics & Outcomes Research, Novartis, spoke on meeting payer and HTA evidence requirements from a Novartis perspective.
Notable speakers at the event included Sun Lihua, Professor, Shenyang Pharmaceutical University who presented on pharmacoeconomic evaluation methodologies; CEO of Fountain Medical, Dan Zhang, who discussed applying pharmacoeconomics successfully in a modern Chinese company and Manny Papadimitropoulos, PhD, Director, Outcomes Research ICR & Japan, Eli Lilly who gave an overview of pharmacoeconomics for health care decision-makers. Highlights at the event were the panel discussions, held by both Dan Zhang and Manny Papadimitropoulos, on how to implement pharmacoeconomics successfully in China and developing your pharmacoeconomic strategy. Special mention should be made to the event sponsor, Axellia who made a significant contribution to the success of the congress.
Other speakers included Nora-Elisabeth Haberg, Sales & Marketing Director, Axellia; Liu Kejun, Deputy Researcher, China Health Economics Institute, Ministry of Health; Ma Aixia, Professor, China Pharmaceutical University; Libo Tao, Health Economics & Outcome Research Manager, Beijing Novartis Pharma Co Ltd and Hugues Malonne, Outcomes Research Director, Merck. Topics discussed included health economics in northern Europe, a comprehensive study of the post-market re-evaluation of high blood pressure medicine, the HPV vaccine on the market and HTA & OR, the pharmaceutical industry's perspective.